Disclosures A.M. has received research grants from Pfizer, Ionis, Attralus, and Cytokinetics and personal fees for consulting and steering committee membership from Cytokinetics, BMS, BridgeBio Pharma, Pfizer, Ionis, Lexicon, Attralus, Haya, BioMarin, Alexion, and Tenaya. M.G. has received research grants from Alnylam Pharmaceuticals, BridgeBio Pharma, Janssen Pharmaceuticals, and Pfizer and personal fees for consulting and steering committee membership from Janssen Pharmaceuticals and Novo Nordisk. D.J. is a current employee of Cytokinetics and has received research funding from BMS. M.S.M. has received grants and personal fees from Alnylam, Pfizer, BridgeBio Pharma, Prothena, and Ionis and personal fees from AstraZeneca, Akcea, Intellia, and Novo Nordisk. S.J.S. is supported by grants from the National Heart, Lung, and Blood Institute (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423), has received research grants from AstraZeneca, Corvia and Pfizer and has received consulting fees from Abbott, Alleviant, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, Cyclerion, Cytokinetics, Edwards Lifesciences, BridgeBio Pharma, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, ReCor, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya, and Ultromics. R.W. reports research grants and personal fees from Alnylam, Pfizer, BridgeBio Pharma, Ionis, and Janssen Pharmaceuticals and personal consulting fees from AstraZeneca, Novo Nordisk, and Alexion. P.W.W. is a former employee and shareholder of BridgeBio Pharma. A.X.J., J.D., S.S., L.K., U.S., and J.C.F. are employees and shareholders of BridgeBio Pharma. D.P.J. has received personal consulting fees from Alexion, Alleviant Medical, Attralus, BridgeBio Pharma, Cytokinetics, Lexeo Therapeutics, Novo Nordisk, Renovacor, and Tenaya Therapeutics. M.A. has nothing to disclose.